Abstract Details

Title Correlates of Anti-AQP4 Autoantibody Serostatus Among NMOSD Participants in the CIRCLES Study

Topic General Neurology

Presentation(s) P9 - Poster Session 9 (12:00 PM-1:00 PM)

Poster/Presentation
Number 6-010

Objective To explore clinical correlates in neuromyelitis optica spectrum disorder (NMOSD) participants enrolled in the Collaborative International Research in Clinical and Longitudinal Experience for NMOSD Studies (CIRCLES) natural history study.

Background NMOSD is a rare autoimmune disease frequently causing serious cumulative neurological disability. Anti-AQP4 Ab serostatus may play key roles in clinical course and outcomes in NMOSD. Uncertainties remain regarding potential differences between anti-AQP4 antibody-positive and –negative disease phenotypes.

Design/Methods Participants were recruited at geographically dispersed centers in North America from November 2013 through June 2018. NMOSD diagnosis using (Wingerchuck 2006 or IPND 2015 criteria) and anti-AQP4 antibody serostatus was established at time of subject enrollment. Gender, race, age and clinical features at disease onset were analyzed. Potential relationships between NMOSD and comorbid conditions were also analyzed. Cases and control subjects were compared as were participants with versus without detectable anti-AQP4 antibody. Analyses utilized descriptive statistics and chi-square or Wilcoxon rank sum tests.

Results A total of 649 NMOSD cases and 275 controls met inclusion criteria. Compared to seronegative cases, anti-AQP4 antibody-seropositive participants were more likely to be female (87.3% vs. 74.3%, p<0.001); black or African American (25.9% vs. 10.6%); Hispanic or Latino (12.9% vs. 6.2%) (p<0.001); and older at disease onset (38.4 years vs 32.5, p<0.001). Seronegative cases were more likely to experience optic neuritis, transverse myelitis, and bladder bowel dysfunction related presentations during initial NMOSD attack. Compared to controls, NMOSD participants were more likely to have Sjogren’s syndrome (p=0.006) or systemic lupus erythematosus (p=0.038) comorbidity and a consanguineous relative with an autoimmune diagnosis (p<0.001).

Conclusions Significant differences in age, gender, ancestry and comorbidity correlated with anti-AQP4 serostatus in NMOSD participants, despite similar clinical characteristics. Studies to assess such relationships beyond the CIRCLES cohort are ongoing. CIRCLES is a valuable resource for accelerating advances to understand and solve NMOSD.

Authors/Disclosures
Lawrence Cook, PhD (University of Utah Data Coordinating Center) PRESENTER	The institution of Dr. Cook has received research support from CDC. The institution of Dr. Cook has received research support from The Guthy-Jackson Charitable Foundation. The institution of Dr. Cook has received research support from Utah Highway Safety Office. The institution of Dr. Cook has received research support from NIH.
	No disclosure on file
John W. Rose, MD, F�鶹��ýӳ�� (Imaging and Neurosciences Center)	The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Anna Jolley (University of Utah, Data Coordinating Center)	Ms. Jolley has nothing to disclose.
	No disclosure on file
	No disclosure on file
Megan Behne (The Guthy-Jackson Charitable Foundation)	Ms. Behne has received personal compensation for serving as an employee of The Guthy-Jackson Charitable Foundation. Ms. Behne has received personal compensation in the range of $50,000-$99,999 for serving as a Independent Contractor with The Guthy-Jackson Charitable Foundation.
	No disclosure on file
Jacinta Behne (The Guthy-Jackson Charitable Foundation)	Ms. Behne has nothing to disclose.
	No disclosure on file
Terry Smith	Terry Smith has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Horizon. Terry Smith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Immunovant. Terry Smith has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Terry Smith has received intellectual property interests from a discovery or technology relating to health care.
Michael R. Yeaman, PhD (UCLA)	Dr. Yeaman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Yeaman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genentech-Roche. Dr. Yeaman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Dr. Yeaman has received research support from National Institutes of Health. The institution of Dr. Yeaman has received research support from U.S. Department of Defense. Dr. Yeaman has received intellectual property interests from a discovery or technology relating to health care. Dr. Yeaman has received intellectual property interests from a discovery or technology relating to health care.

�鶹��ýӳ��

�鶹��ýӳ��